AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05631886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TP53-EphA-2-CAR-DC
Description: 5\~10 × 10\^6 CAR DCs per dose will be administered by intravenous injection.
Study NCT05631886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Intravenous abraxane 125 mg/m\^2/day on day-5.
Study NCT05631886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
Study NCT05631886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: Intravenous anti-PD-1 antibody 200 mg/day.
Study NCT05631886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CTLA4 Monoclonal Antibody
Description: Intravenous anti-CTLA4 antibody 1 mg/kg/day
Study NCT06137404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: Comparison of splints for trigger finger
Study NCT06137404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: Comparison of splints for trigger finger
Study NCT05534750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid arm (SIVEXTRO®)
Description: Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
Study NCT05534750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid arm (ZYVOXID®)
Description: Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
Study NCT05991518 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine+Cisplatin
Description: Gemcitabine is administered at a dose of 1000 mg/m2 on the second day (D2) and ninth day (D9) of each cycle. At least 6 hours after the completion of gemcitabine infusion, cisplatin is administered at a dose of 70 mg/m2 on the second day (D2) of each cycle.
Study NCT04510844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab is commercially available in the United States and is manufactured by Amgen. Drug and placebo, will be supplied by the manufacturer. The SureClick® pre-filled auto injector contain Evolocumab (140 mg) acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in water for Injection. Evolocumab will be administered at a dose of 420 mg subcutaneously once monthly.
Study NCT04510844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied by the manufacturer. Placebo auto injectors will be identically packaged but will lack the active ingredient. Placebo will be administered at an equivalent volume to Evolocumab and given subcutaneously once monthly.
Study NCT05859776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 Low Dose
Description: Single suprachoroidal injection of AXT107 (0.125 mg/eye)
Study NCT05859776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 Mid Dose
Description: Single suprachoroidal injection of AXT107 (0.250 mg/eye)
Study NCT05859776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 High Dose
Description: Single suprachoroidal injection of AXT107 (0.500 mg/eye)
Study NCT06010186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of the diaphragm and intercostals
Description: The specific research procedures correspond to the addition of :~* Two additional ultrasound examinations, i.e. at discharge from intensive care and 3 months after hospital discharge: non-invasive examination (duration 20 minutes). Ultrasound is a risk-free, painless procedure involving the placement of an ultrasound probe on the body part under investigation, without the need for a radius or puncture.~* Questionnaires to assess quality of life (SF-36) and functional impact (LCADL) of dyspnea, carried out at discharge from hospital and at 3 months (duration 15 minutes).
Study NCT05007301 — intervention group
Intervention type: DEVICE
Intervention: geko device
Description: Neuromuscular electrostimulation of the peroneal nerve, 12h per day, for up to 12 weeks.
Study NCT05534750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard quadruple therapy arm
Description: Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms.
Study NCT04287803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores >=4
Study NCT05497258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assistant system
Description: The AI-assisted diagnosis system can provide the direction of disease diagnosis in real time and assist the doctor to give the final diagnosis
Study NCT05754515 — intervention group
Intervention type: PROCEDURE
Intervention: target controlled infusion (TCI) group
Description: Patients in the TCI group will be anesthetized with propofol and remifentanil throughout the operation.~Patients included in the inhalation anesthesia group will be anesthetized with desflurane and remifentanil with a bispectral index of 40-60 throughout the operation.
Study NCT06520631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice packs (cryotherapy)
Description: One group of patients receives ice pack applied on the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.~The second group of patients receives ice pack applied on contralateral to the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.
Study NCT06378645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia: Propofol
Description: Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Propofol will be administered intravenously using the target-controlled infusion algorithm with effect site concentrations between 1.5-4.0 µg/ml necessary.
Study NCT06378645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia: Sevoflurane
Description: Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Sevoflurane will be given in gaseous form via the endotracheal tube in concentrations between 1.5-2.5% Vol.
Study NCT06287619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoferric Injectable Product
Description: Ferric derisomaltose will be prepared by an unblinded research pharmacist as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.
Study NCT06287619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: Patients in the control group will receive placebo, which will be 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing according to good manufacturing practice (GMP).
Study NCT05471102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Study group: lower segment resection with ligation of the anterior division of the internal iliac artery
Description: Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
Study NCT05471102 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group: lower segment resection without ligation of the anterior division of the internal iliac artery
Description: Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
Study NCT04890639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Four hypoxia sessions, consisting of 15 cycles of hypoxia (21%, 17%, 13% or 9% O2), each of which lasts up to 60 seconds, interspersed with up to 90-second normoxic episodes.
Study NCT05210010 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CA-4F
Description: The study intervention is the CA-4F algorithm developed by Ensho Health.~The algorithm is a process for converting input parameters to a CA-4F Risk Score intended to facilitate clinical prioritization of patients suitable for follow-up investigation for ATTR-CM.~The algorithm is applied using the CA-4F Likelihood Estimator which encodes it in software and records its outputs. The CA-4F Likelihood Estimator is controlled through a graphical user interface called the CA-4F Controller.~The CA-4F Likelihood Estimator and its Controller are Class I medical devices in Canada registered under the Medical Device Establishment License of Ensho Health (license 16208).
Study NCT05998200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA
Description: Participants will used the serum twice daily for 8 weeks
Study NCT05725954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GUT LINK SmartPath
Description: A virtual care delivery and referral support tool for primary healthcare providers.
Study NCT06482476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Lp(a) levels
Description: Collection of a venous blood sample for the measurement of Lp(a) levels using standardized laboratory methods
Study NCT04734249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib(HMPL-012)
Description: 1. Cohort 1:Surufatinib(250mg ,qd,po)+mFOLFOX6/FOLFIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~   Cohort 2:Surufatinib(250mg ,qd,po)+FOLFOXIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~2. if the first-line chemotherapy was used FoLFOX ,the second-line is FOLFIRI,or the first-line chemotherapy was used FOLFIRI ,the second-line is FoLFOX.~3. Second-line Surufatinib Combined With Chemotherapy in Advanced CRC.
Study NCT05924997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab, camrelizumab plus apatinib
Description: adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
Study NCT04883528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
Study NCT04883528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
Study NCT05536622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution infrared imaging
Description: High resolution infrared imaging of limb of concern and unaffected limb (control).
Study NCT06279689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scans
Description: Ultrasound scans connected with an application enabling the measurement of the force applied.
Study NCT04748965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Subtraction Angiography
Description: Compare optical coherence tomography lesion sizing and characteristics compared to traditional digital subtraction angiography
Study NCT06176651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miebo
Description: Subjects will be instructed to use the Miebo eye drop four times per day in both eyes during their participation in clinical trial. The subjects will be required to remove their contact lenses prior to instillation of the Miebo eye drop and must wait 30 minutes before reinserting their contact lenses.
Study NCT04731792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: a bronchial fibroscopy with a virtual reality helmet
Study NCT04810065 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SingStrong: Strong lungs through Song
Description: Participants who have been clinically diagnosed with Covid-19 and who continue to suffer residual adverse effects on the lung health will be invited to participate in the study.~The intervention will involve biweekly hour-long breathing and singing classes that are designed to correct dis-ordered breathing, and retrain the principal muscles of respiration.~Pre and post evaluation of participant bio-psychosocial health and wellness will be conducted. Triangulation of data using focus groups and individual interviews will be conducted after conclusion of the intervention,
Study NCT04874805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of oxygen saturation
Description: Measurement of oxygen saturation by pulse oximetry once a day, at 6 a.m., for a minimum of 3 days, thanks to three pulse oximeters (1 measurement point per device/day), in parallel with a synchronous sampling, programmed as part of the usual care, of arterial gasometry.
Study NCT04001946 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Button Huggie
Description: low profile, external securement device for G-buttons
Study NCT05651607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral solution, taken 3 times a day (morning, noon and evening), 5 mg/kg/day from day D0 to day D4. If not effective and well tolerated, dose increase : 10 mg/kg/day from day D5 to day D9, then 20 mg/kg/day from day D10 to day D29, maximum 800 mg/day
Study NCT04624334 — intervention group
Intervention type: OTHER
Intervention: Elektro-Entero-Graphy procedure
Description: Fasting, after which pre- and postprandial EEnG measurements are performed.
Study NCT04624334 — intervention group
Intervention type: OTHER
Intervention: EEnG Questionnaire
Description: Filling out questionnaire about EEnG procedure.
Study NCT04624334 — intervention group
Intervention type: OTHER
Intervention: Gold Standard Questionnaire
Description: Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.
Study NCT04317157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Specific dosage of caffeine for each participant (6 mg.kg-1).
Study NCT04317157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pill.
Study NCT04317157 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill.
Study NCT05302258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Attenuation imaging in ultrasonography
Description: Attenuation imaging in ultrasonography
Study NCT04656106 — intervention group
Intervention type: DRUG
Intervention: Ryzodeg®
Description: All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
Study NCT06299722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STEEL
Description: Relatively heavy strength training
Study NCT06299722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circuit training
Description: Circuit training
Study NCT06028308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone playing a sound
Description: A sound will be played from a portable device (smartphone mounted with earphones) during movement
Study NCT05503147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
Study NCT04933942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Oral administration of Lomustine
Study NCT04933942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Oral administration of Lomustine
Study NCT04933942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Subcutaneous administration of Romiplostim
Study NCT06437899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravesical botulinum toxin A injection unter local anaesthesia
Description: Arm1: Botulinum toxin A injection under local anesthesia according to standard protocol:~Retrograde filling of the empty urinary bladder with a 1:1 mixture of 50 ml lidocaine 1% mixed with 50 ml sodium bicarbonate 8.4%, leave the local anesthetic mixture in the bladder for 15 minutes.~Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10 ml NaCl 0.9% into the detrusor at 10 points using a rigid 70 degree cystoscope~Arm 2: botulinum toxin A injection in sedoanalgesia according to the anesthesia standard protocol:~Intravenous administration of remifentanil (0.05-0.15µg/kg/min) and propofol. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10ml NaCl 0.9% into the detrusor.
Study NCT04924296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314 s.c. + Steroids
Study NCT04924296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. + Steroids
Study NCT05030064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intestinal flora capsule
Description: This research group has independently researched and created a human intestinal flora capsule based on intestinal bacteria transplantation: Intestinal flora capsule, which has been declared a national invention patent (patent number: 2015103040414).
Study NCT05030064 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Each placebo capsule is the two-layer empty capsule shell of the Intestinal flora capsule, which is made of titanium dioxide and iron oxide yellow. It is non-toxic and has the same appearance as the authentic Intestinal flora capsule.
Study NCT05639322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.
Study NCT05639322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12
Study NCT05639322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine + Cognitive Behavioral Therapy
Description: Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.
Study NCT05324423 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine
Description: Colchicine0.5 mg Oral Tablet Day-7\~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
Study NCT05942118 — intervention group
Intervention type: PROCEDURE
Intervention: Breast conservative surgery
Description: Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
Study NCT04871802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taxifolin Aqua
Description: Dietary supplement
Study NCT05088993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill training
Description: This group received antigravity treadmill training 100% weight bearing
Study NCT05088993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise program
Description: This group received the conventional exercise program only.
Study NCT05088993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise program
Description: This group received the conventional exercise program only.
Study NCT05209308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib
Description: Zandelisib taken orally for 7 days of each 28 day cycle
Study NCT05209308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV for 6 cycles
Study NCT05209308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally - Ramp up weeks 1-5
Study NCT05313074 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac vaccine
Description: An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
Study NCT05313074 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CoronaVac vaccine
Description: An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.